| A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria MA Phillips, J Lotharius, K Marsh, J White, A Dayan, KL White, ... Science translational medicine 7 (296), 296ra111-296ra111, 2015 | 328 | 2015 |
| Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate AM Lisewski, JP Quiros, CL Ng, AK Adikesavan, K Miura, N Putluri, ... Cell 158 (4), 916-928, 2014 | 147 | 2014 |
| Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax … A Llanos-Cuentas, M Casapia, R Chuquiyauri, JC Hinojosa, N Kerr, ... The Lancet Infectious Diseases 18 (8), 874-883, 2018 | 138 | 2018 |
| Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study JS McCarthy, J Lotharius, T Rückle, S Chalon, MA Phillips, S Elliott, ... The Lancet Infectious Diseases 17 (6), 626-635, 2017 | 130 | 2017 |
| A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue E Sonoiki, CL Ng, MCS Lee, D Guo, YK Zhang, Y Zhou, MRK Alley, ... Nature communications 8, 14574, 2017 | 121 | 2017 |
| Animal Models for SARS‐CoV‐2 research: A Comprehensive Literature Review K Pandey, A Acharya, M Mohan, CL Ng, PS Reid, SN Byrareddy Transboundary and emerging diseases, 2020 | 78 | 2020 |
| CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds but potentiates artemisinin … CL Ng, G Siciliano, M Lee, MJ de Almeida, VC Corey, SE Bopp, ... Molecular microbiology 101 (3), 381-393, 2016 | 66 | 2016 |
| Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents BH Stokes, E Yoo, JM Murithi, MR Luth, P Afanasyev, PCA da Fonseca, ... PLoS pathogens 15 (6), e1007722, 2019 | 63 | 2019 |
| Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors E Yoo, BH Stokes, H de Jong, M Vanaerschot, TRS Kumar, N Lawrence, ... Journal of the American Chemical Society 140 (36), 11424-11437, 2018 | 56 | 2018 |
| Protein degradation systems as antimalarial therapeutic targets CL Ng, DA Fidock, M Bogyo Trends in parasitology 33 (9), 731-743, 2017 | 50 | 2017 |
| Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19) OA Olwenyi, SR Dyavar, A Acharya, AT Podany, CV Fletcher, CL Ng, ... Journal of Molecular Medicine, 1-15, 2020 | 49 | 2020 |
| Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the … J White, SK Dhingra, X Deng, F El Mazouni, MCS Lee, GA Afanador, ... ACS infectious diseases 5 (1), 90-101, 2018 | 49 | 2018 |
| Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling A Le Bihan, R de Kanter, I Angulo-Barturen, C Binkert, C Boss, R Brun, ... PLoS Med 13 (10), e1002138, 2016 | 47 | 2016 |
| Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity M Vanaerschot, L Lucantoni, T Li, JM Combrinck, A Ruecker, TRS Kumar, ... Nature Microbiology 2 (10), 1403, 2017 | 46 | 2017 |
| P. falciparum artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response MR Rosenthal, CL Ng ACS Infectious Diseases, 2020 | 43 | 2020 |
| TetL Tetracycline Efflux Protein from Bacillus subtilis Is a Dimer in the Membrane and in Detergent Solution M Safferling, H Griffith, J Jin, J Sharp, M De Jesus, C Ng, TA Krulwich, ... Biochemistry 42 (47), 13969-13976, 2003 | 40 | 2003 |
| TRAM1 participates in human cytomegalovirus US2-and US11-mediated dislocation of an endoplasmic reticulum membrane glycoprotein K Oresic, CL Ng, D Tortorella Journal of Biological Chemistry 284 (9), 5905-5914, 2009 | 31 | 2009 |
| Plasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing CL Ng, DA Fidock Malaria Control and Elimination, 123-140, 2019 | 27 | 2019 |
| A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7: 296ra111 MA Phillips, J Lotharius, K Marsh, J White, A Dayan, KL White, ... | 27 | 2015 |
| TRAM1 is involved in disposal of ER membrane degradation substrates CL Ng, K Oresic, D Tortorella Experimental cell research 316 (13), 2113-2122, 2010 | 26 | 2010 |
David FidockProfessor of Microbiology & Immunology and of Medical Sciences (in Medicine), Columbia University在 columbia.edu 的电子邮件经过验证
